标新生物GT919联合用药临床研究正式获批

发布日期：2024-03-12 文章来源：标新生物

今日，标新生物（Gluetacs Therapeutics）GlueTacs^®平台开发的分子胶管线GT919经CDE默许，进入多发性骨髓瘤系统性联合治疗阶段，探究安全性以及有效性的初步评估。

Today, Gluetacs Therapeutics’ molecular glue pipeline GT919, developed on the GlueTacs^® platform, receives approval from CDE to enter the systemic combination therapy stage for multiple myeloma, undergoing preliminary evaluation of safety and efficacy.